Trial Profile
A phase I, open-label, randomized, single-dose, three-way crossover study comparing the bioavailability of ELI-200 with a reference product under fed conditions in healthy volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2015
Price :
$35
*
At a glance
- Drugs ELI 200 (Primary) ; Opioid analgesics
- Indications Pain
- Focus Pharmacokinetics
- 19 Feb 2015 New trial record
- 17 Feb 2015 According to an Elite Pharmaceuticals media release, dosing for this study has been completed.